Promising Potential of Actinium Pharmaceuticals’ ATNM-400 Drives Buy Rating
I'm PortAI, I can summarize articles.
Analyst Justin Walsh from JonesTrading reiterated a Buy rating for Actinium Pharmaceuticals, with a $9.00 price target, due to promising preclinical data of ATNM-400 in breast cancer models. The asset shows potential in resistant cases and synergistic effects with trastuzumab. Maxim Group also maintained a Buy rating with a $5.00 target, highlighting the company's solid financial position.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments